Tag Archives: MammaPrint

Next-generation DNA sequencing (NGS) is rapidly becoming an indispensable tool for genome-directed cancer diagnostics, but next-generation RNA sequencing (RNA-seq) is currently not standardly used in clinical diagnostics for expression assessment. However, multi-gene RNA diagnostic assays are used increasingly in the ...

Agilent Technologies Inc. (NYSE: A) and Agendia, Inc. today jointly announced an agreement to expand their relationship to include the development of an RNA-Seq kit version of Agendia’s currently marketed MammaPrint and BluePrint tests. Agendia’s MammaPrint test provides High-Risk or ...